Separate names with a comma.
2026 Annual General and Special Meeting of Shareholders https://central.virtualshareholdermeeting.com/vsm/web?pvskey=DFTX2026 DEFINIUM...
ModuLink Provides Commercial Pipeline Update for LUNA AI System in Hong Kong...
Is this finally the breakthrough moment for psychedelic therapies?...
Definium Therapeutics | Rethinking Psychedelic Treatment for Mental Health [MEDIA]
Americans are increasingly open to using psychedelics for medical reasons...
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder...
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update...
Watch May 19th at 8:30AM EST - Rethinking Psychedelic Treatment for America's Mental Health Crisis [MEDIA] Psychiatry is at an inflection...
PANEL: Clinical Risk, Regulatory Reality and the Path to Scale - Needham Virtual Psychedelics Forum $DFTX $ATAI $CMPS...
The Latest Data on Psychedelic DT120 ODT With Daniel R. Karlin, MD, MA Videos|April 27, 2026...
Accelerated FDA Action for Psychedelics: Insights From Daniel R. Karlin, MD, MA Author(s)Daniel R. Karlin, MD, MA Definium’s CMO says FDA talks...
$ATAI DemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)...
Definium Therapeutics Investor Day - April 22, 2026 [MEDIA]
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day April...
Apeiron’s Christian Angermayer on using psychedelic drugs for mental health treatment...
[IMG] Investor & Analyst Day Date: Wednesday, April 22, 2026 Time: 10:00 am – 12:00 pm ET, followed by lunch Location: Virtual Link below...
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder...
Mad Money 04/20/26 | Audio Only DFTX Interview at 27:00 [MEDIA]
